The global transfection technologies market size reached USD 1,258.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,338.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.1% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 1,258.9 Million |
Market Forecast in 2033
|
USD 2,338.7 Million |
Market Growth Rate 2025-2033 | 7.1% |
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global transfection technologies market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product type, application, transfection method, technology and end-user.
Breakup by Product Type:
Breakup by Application:
Breakup by Transfection Method:
Breakup by Technology:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product Type, Application, Transfection Method, Technology, End-User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global transfection technologies market was valued at USD 1,258.9 Million in 2024.
We expect the global transfection technologies market to exhibit a CAGR of 7.1% during 2025-2033.
The increasing prevalence of cancer and various chronic lifestyle diseases, along with the rising utilization of advanced transfection technologies in drug discovery, target validation, and cellular research, is primarily driving the global transfection technologies market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of transfection technologies for the development of novel vaccines and therapeutic drugs to combat the risk of the coronavirus infection.
Based on the product type, the global transfection technologies market has been divided into reagent, instrument, and others. Among these, reagent currently exhibits a clear dominance in the market.
based on the application, the global transfection technologies market can be categorized into therapeutic delivery, bio-medical research, protein production, and others. Currently, bio-medical research accounts for the majority of the global market share.
Based on the transfection method, the global transfection technologies market has been segregated into lipofection, eletroporation, nucleofection, cotransfection, cationic lipid transfection, in-vivo transfection, and others. Among these, electroporation currently exhibits a clear dominance in the market.
Based on the technology, the global transfection technologies market can be bifurcated into physical transfection, biochemical based transfection, and viral-vector based transfection. Currently, biochemical based transfection holds the largest market share.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global transfection technologies market include Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.